EGFR and non-small cell lung carcinoma: Currently, the combination of a PARP inhibitor (niraparib) and anti-PDL1 durvalumab is being tested in EGFR-mutant NSCLC that has transformed to a SCLC phenotype in a phase II clinical trial (NCT04538378).